AbbVie is shutting down its troubled Rova-T R&D program [MarketWatch]
Last abbvie, inc earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations: investors.abbvie.com/investor-overview
AbbVie is shutting down its troubled Rova-T R&D program Shares of AbbVie Inc. ABBV, +0.74% rose 1.5% in premarket trade Thursday after the company announced it had shut down its troubled Rova-T research and development program. The drugmaker said it was discontinuing a late-stage trial of Rova-T as a potential treatment for advanced small-cell lung cancer after interim data showed patients on the drug had no survival benefit compared with those on placebo. "Small-cell lung cancer continues to be one of the most difficult-to-treat cancers where there is a significant need for transformative therapies. We are disappointed with this outcome for the patients who suffer from this disease," said Margaret Foley, global head of solid tumor development at AbbVie. The closure of the Rova-T program comes after several other trial setbacks for the drug. AbbVie bought Stemcentrx and its prized investigational drug in 2016 for $5.8 billion in cash and stock, but was forced to put down an impairm
[Read more]
| Impact snapshot | Event time: | ABBV | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ABBV alerts
ABBV alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie, Inc news events
Weekly update
A roundup of the hottest topics
ABBV
News
- AbbVie Inc. (<a href="https://www.marketbeat.com/stocks/NYSE/ABBV/price-target/">NYSE: ABBV</a>) is now covered by analysts at Truist Securities. They set a "buy" rating and a $117.00 price target on the stock.MarketBeat
- AbbVie Inc. (<a href="https://www.marketbeat.com/stocks/NYSE/ABBV/price-target/">NYSE: ABBV</a>) is now covered by analysts at Truist. They set a "buy" rating and a $124.08 price target on the stock.MarketBeat
- AbbVie and Calico Announce Second Extension of Collaboration Focused on Aging and Age-Related DiseasesPR Newswire
- New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye ConditionPR Newswire
- DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric PatientsPR Newswire
- More
ABBV
SEC Filings
- 7/2/21 - Form 4
- 7/2/21 - Form 4
- 7/2/21 - Form 4
- ABBV's page on the SEC website
- More